Skip to main content

Table 1 Clinical features of 90 newly diagnosed type 2 diabetic patients at baseline and after CSII

From: Effect of intensive insulin treatment on plasma levels of lipoprotein-associated phospholipase A2 and secretory phospholipase A2 in patients with newly diagnosed type 2 diabetes

 

Baseline

After CSII

kind of test

P

Waist circumference (cm)

87.49 ± 8.26

86.80 ± 7.93

paired t-test

0.021

Body mass index (kg/m2)

24.03 ± 2.93

23.85 ± 2.90

paired t-test

0.149

Systolic pressure (mmHg)

129 ± 14

121 ± 11

paired t-test

<0.01

Diastolic pressure (mmHg)

83 ± 10

76 ± 7

paired t-test

<0.01

HbA1c (%)

11.70 ± 2.40

9.82 ± 2.02

paired t-test

<0.01

IVGTT AUCGlu

89.43 ± 17.38

67.01 ± 11.74

paired t-test

<0.01

OGTT AUCGlu

79.57 ± 18.88

46.49 ± 9.28

paired t-test

<0.01

Total cholesterol (mmol/L)

5.82 ± 1.21

4.89 ± 0.95

paired t-test

<0.01

Triglyceride (mmol/L)

1.76 (1.26,3.05)

1.74 (1.29,2.24)

Wilcoxon rank sum test

0.026

HDL-C (mmol/L)

1.18 ± 0.29

1.23 ± 0.29

paired t-test

0.035

LDL-C (mmol/L)

3.73 ± 0.98

2.93 ± 0.77

paired t-test

<0.01

hsCRP (mg/L)

1.84 (1.08,3.67)

1.69 (0.77,2.96)

Wilcoxon rank sum test

0.54

White blood cells (×109/L)

7.62 ± 2.02

6.75 ± 1.70

paired t-test

<0.01

Free fatty acid (umol/L)

607.48 ± 225.00

469.11 ± 171.41

paired t-test

0.004

HOMA-IR

1.45 (1.01, 2.45)

0.96 (0.68, 1.85)

Wilcoxon rank sum test

<0.01

IAI

0.03 (0.02, 0.04)

0.05 (0.02, 0.06)

Wilcoxon rank sum test

<0.01

QUICKI

0.67 ± 0.12

0.74 ± 0.15

paired t-test

<0.01

ISIced

5.89 (4.33, 7.26)

9.68 (8.25, 11.69)

Wilcoxon rank sum test

<0.01

HOMA-β

6.87 (4.40, 15.73)

21.00 (12.90,43.04)

Wilcoxon rank sum test

<0.01

AIR3–5

1.38 (0, 5.25)

3.80 (0.87,7.46)

Wilcoxon rank sum test

<0.01

∆Ins30/∆G30

0.19 (0, 1.01)

1.80 (0.60, 3.29)

Wilcoxon rank sum test

<0.01

MBCI

0.91 (0.73, 1.70)

1.12 (0.74, 2.15)

Wilcoxon rank sum test

0.048

IVGTT AUCIns

11.91 (8.00,29.05)

25.64 (10.32,46.79)

Wilcoxon rank sum test

<0.01

OGTT AUCIns

27.60 (12.20,64.37)

75.45 (46.37,123.53)

Wilcoxon rank sum test

<0.01

HOMA-β/HOMA-IR

4.84 (2.60, 9.59)

20.99 (12.50,31.78)

Wilcoxon rank sum test

<0.01

AIR3–5/HOMA-IR

0.95 (0, 2.86)

2.49 (0.45, 6.22)

Wilcoxon rank sum test

<0.01

∆Ins30/(∆G30× HOMA-IR)

0.16 (0, 0.37)

1.11 (0.50, 2.75)

Wilcoxon rank sum test

<0.01

MBCI/HOMA-IR

0.71 (0.55, 0.92)

1.16 (1.01,1.34)

Wilcoxon rank sum test

<0.01

IVGTT AUCIns/

HOMA-IR

9.98 (6.58, 14.82)

21.25 (12.62,31.92)

Wilcoxon rank sum test

<0.01

OGTT AUCIns/HOMA-IR

17.91 (10.01,35.70)

64.35 (47.82,93.13)

Wilcoxon rank sum test

<0.01

Lp-PLA2 (ng/ml)

102.9 (76.34,134.31)

88.35 (76.74,125.18)

Wilcoxon rank sum test

0.087

sPLA2 (ng/ml)

219.33 (130.03,337.30)

173.78 (80.95,278.09)

Wilcoxon rank sum test

<0.01

  1. Abbreviations: HbA1c hemoglobin A1c, IVGTT AUC Glu the areas under the curve of glucose in intravenous glucose tolerance test, OGTT AUC Glu the areas under the curve of glucose in oral glucose tolerance test, HDL-C high density lipoprotein cholesterol, LDL-C low density lipoprotein cholesterol, hsCRP high sensitivity C reactive protein; HOMA-IR, IAI, QUICKI and ISI ced are indicators of insulin sensitivity (HOMA-IR = FPG × FIns/22.5; IAI = 1/(FIns × FPG); QUICKI = 1/(lgFPG + lgFIns); ISIced = MCR/LgMSI, MCR = M/MG, MG = (FPG + Glu30 min + Glu60 min + Glu120 min)/4, MSI = (FIns + Ins30 min + Ins60 min + Ins120 min)/4, M = 75000/120 + (FPG - Glu120 min) × 1.15 × 180 × 0.19 × body weight/120), HOMA-β, AIR 3–5 ∆Ins30/∆G30, MBCI, IVGTT AUCIns and OGTT AUCIns are indicators of island function (HOMA-β = 20 × FIns/(FPG - 3.5); AIR3–5 is calculated as the average increase of plasma insulin between the 3rd or 5th minute and the base line in IVGTT; ∆Ins30/∆G30 = (Ins30min - FIns)/(Glu30min - FPG); MBCI = (FPG × FIns)/(Glu120min + Glu60min - 7); AUCIns, the area under the curve (AUC) of insulin, IVGTT AUCIns = (3 × FINS+ 5 × INS3+ 4 × INS5+ 5 × INS7+ 3 × INS10)/2, OGTT AUCIns = (FINS + 2 × INS30+ 3 × INS60+ 4 × INS120+ 2 × INS180)/4; all the indicators regarding to β cell function were respectively divided by HOMA-IR to guarantee from interference of insulin resistance), Lp-PLA 2 lipoprotein-associated phospholipase A2, sPLA 2 secretory phospholipase A2
  2. Data are expressed as median (interquartile range) or mean ± SD
  3. Values of P < 0.05 are statistically significant